Join to View Full Profile
1725 W Harrison StSuite 1010Chicago, IL 60612
Phone+1 312-942-5904
Dr. Rao is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Rush University Medical CenterFellowship, Hematology and Medical Oncology, 2002 - 2005
University of Illinois College of Medicine at ChicagoResidency, Internal Medicine, 2000 - 2002
University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Internal Medicine, 1999 - 2000- University of Southern California/LACUSC Medical CenterInternship, Transitional Year, 1998 - 1999
University of Wisconsin School of Medicine & Public HealthClass of 1998
Certifications & Licensure
IL State Medical License 2001 - 2026
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory EHR Suite, Epic Systems Corporation, 2012-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012-2017
Clinical Trials
- Phase II Open-Label Trial of Tarceva in Women With Metastatic, Hormone- and HER2-Negative Breast Cancer Start of enrollment: 2007 Apr 01
- A Study of Abemaciclib (LY2835219) Plus Hormone Therapy in Participants With Early Breast Cancer Start of enrollment: 2021 May 10
- A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer Start of enrollment: 2021 Oct 04
Publications & Presentations
PubMed
- A prospective study of serum folate levels in patients with solid tumors treated with olaparib.Jamile Shammo, Laura Owczarzak, Nicole K Yun, Lois Winkelman, Sanjib Basu
The Oncologist. 2025-10-01 - 1 citationsPhase 2 trial of imprime and pembrolizumab immunotherapy in metastatic triple negative breast cancer patients who have progressed beyond first line chemotherapy.Alison T Stopeck, Maysa Abu-Khalaf, Virginia Borges, Bartosz Chmielowski, Ruta Rao
Journal of Immunology. 2025-07-01 - 28 citationsMulticenter retrospective cohort study of the sequential use of the antibody-drug conjugates (ADCs) trastuzumab deruxtecan (T-DXd) and sacituzumab govitecan (SG) in pa...Laura A Huppert, Reshma Mahtani, Samantha Fisch, Naomi Dempsey, Sarah Premji
NPJ Breast Cancer. 2025-04-15
Journal Articles
- Gestational Breast Cancer: Current Challenges in Staging and Treatment of Breast CancerRuta Rao, MD, BMJ Case Reports CP
Press Mentions
New Chicago Breast Cancer Research Consortium Will Increase Access to Clinical TrialsSeptember 4th, 2025- Treatment for HER2-Positive Early Breast Cancer with Residual Invasive Disease After Neoadjuvant TherapyJune 23rd, 2025
- 5 Breast Cancer FactsOctober 1st, 2022
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
